×
For best experience we recommend to activate Javascript in your browser.
Recombinant CD200 (Samalizumab Biosimilar) antibody
This Humanized Chimeric antibody specifically detects CD200 (Samalizumab Biosimilar) . It exhibits reactivity toward Human.
Catalog No. ABIN7597968
$493.40
Plus shipping costs $50.00, if applicable $20.00 dry ice
1 mg ABIN7598288
100 μg ABIN7597968
1 mg ABIN7598288
100 μg ABIN7597968
Delivery in 12 to 15 Business Days
Quick Overview for Recombinant CD200 (Samalizumab Biosimilar) antibody (ABIN7597968)
Target
CD200 (Samalizumab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
All hosts for CD200 (Samalizumab Biosimilar) antibodies
Humanized
Clonality
All clonalities for CD200 (Samalizumab Biosimilar) antibodies
Chimeric
Conjugate
All conjugates for CD200 (Samalizumab Biosimilar) antibodies
This CD200 (Samalizumab Biosimilar) antibody is un-conjugated
Application
Please inquire
Grade
Research Grade
Product Details anti-CD200 (Samalizumab Biosimilar) Antibody
(hide)
Expression System
Mammalian cells
Purpose
Research Grade Samalizumab Biosimilar Antibody
Specificity
OX-2 membrane glycoprotein, MOX2, MOX1, CD200
Purification
Protein A or G purified from cell culture supernatant.
Purity
>95 % by SDS-PAGE.
Isotype
IgG Mix kappa
Alternatives
(show)
Application Details
(hide)
Restrictions
For Research Use only
Handling
(hide)
Format
Liquid
Concentration
1 mg/mL
Buffer
0.01M PBS, pH 7.4.
Storage
4 °C,-20 °C,-80 °C
Storage Comment
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
Expiry Date
12 months
Target Details for CD200 (Samalizumab Biosimilar)
(hide)
Target
CD200 (Samalizumab Biosimilar)
Alternative Name
Samalizumab Biosimilar
Target Type
Biosimilar
Background
OX-2 membrane glycoprotein, MOX2, MOX1, CD200
UniProt
P41217
CAS-No
1073059-33-2
Recently viewed
(hide)
You are here:
Homepage
Recombinant anti-CD200 (Samalizumab Biosimilar) antibody (ABIN7597968)
Chat with us , powered by LiveChat